YOU WONT BELIEVE: Ionis pharmaceuticals | Mind Blowing Facts

A Drug That Could Functionally Cure Hepatitis B Achieved That Goal in 1 in 5 Patients in Two Major Phase 3 Trials

Phase 3 B-Well trials published in NEJM showed bepirovirsen achieved functional cure in 20% of chronic hepatitis B patients — the first phase 3 evidence of this kind for the disease.

Medical Daily · Jul 23

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat · Jul 13

Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures (ESU26 ) are up +0.49%, and September E-mini Nasdaq futures...

Barchart · Jul 9

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

Benzinga · Nov 10, 2025

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.

Benzinga · Sep 22, 2025

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Benzinga · Sep 2, 2025

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Upgrades

Benzinga · Sep 9, 2022

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga · Sep 7, 2022

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

 

Benzinga · Jul 20, 2022

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Benzinga · May 20, 2022